Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
But a serious adverse event and waning enzyme levels raise questions about the data.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
One-year data look encouraging, but etranadez will now not be filed until 2022.